Due to the evolving COVID-19 situation, NPIN may not have the most up-to-date organization changes to services or hours. Please call the organization or visit their website to find out about any changes. This site does not have information about where to get tested for COVID-19. For COVID-19 information please visit: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
Debido a la rápida evolución de la situación con respecto al COVID-19, NPIN podría no tener la información mas actualizada de los servicios u horas de las organizaciones. Por favor llame o visite la página web de la organización para conocer los cambios. Este sitio no tiene información sobre donde hacerse la prueba del COVID-19. Para información sobre el COVID-19 por favor visite: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
This guide is designed to help patients understand and manage HIV/HCV coinfection. The guide states that infection of HCV is the most common coinfection in people with HIV, is categorized as an HIV-related opportunistic illness, and is now the leading cause of death in people with HIV. It also advices persons with HIV/HCV to consult a medical practitioner for diagnosis and treatment of HIV/HCV.
This guide is designed as a general guide to understanding and manage being infected with both hepatitis and HIV. Topics include testing, liver basics, transmission, symptoms, herbs, treatments, and staying healthy. The guide recommends that everyone with HIV get tested for hepatitis C.
This pamphlet is a general guide to hepatitis C, a virus that lives in blood and usually affects and damages the liver. Topics include testing, liver basics, transmission, symptoms, herbs, treatments, and staying healthy.
This serial updates and expands previous CDC guidelines for hepatitis B surface antigen (HBsAg) testing, and includes new recommendations for public health evaluation and management for chronically infected persons and their contacts. Routine testing for HBsAg now is recommended in additional populations with HBsAg prevalence of greater than or equal to 2%: persons born in geographic regions with HBsAg prevalence of greater than or equal to 2%, men who have sex with men, and injection-drug users.
This information sheet discusses interferon-gamma release assays (IGRAs), which are whole-blood tests used in diagnosing both latent TB infection and TB disease. It notes that two IGRAs have been approved by the US Food and Drug Administration (FDA) and are commercially available in the United States. The information sheet explains how the IGRAs work; the advantages, disadvantages, and limitations of IGRAs; steps in administering these tests; interpretation; recommendations on when to use them; and whether IGRAs can be given to persons receiving vaccinations.
This information sheet provides an overview of the chemistry panel. These tests measure various chemicals in the blood to determine whether the body is working correctly. Blood chemistry tests assess calcium, phosphorus, and glucose levels as well as the electrolytes sodium, potassium, chloride, and bicarbonate.